The deal also sees Benchmark acquire a worldwide license to utilise specific Zoetis 'know how' to help drive the future research and development of these aquaculture vaccines.
In addition to vaccine research and manufacturing equipment the portfolio acquired includes a number of developed and partially developed vaccines, seed stocks, isolates and vaccine technologies, which together very significantly advance Benchmark's aquaculture research programmes, and substantially complements the Group's existing research base.
Commenting on the development, Benchmark Chief Executive Officer, Malcolm Pye, said: "We are very pleased to have concluded this agreement with Zoetis as this further increases our capacity to develop and deliver fundamental health solutions to aquaculture. This agreement both substantially enhances our product pipeline and increases our ability to access important world markets in aquaculture in the future".
